News
These certifications are awarded by the Association of Physicians of Barcelona and by the portalesmedicos.com website, respectively. Both organizations committees have praised the accuracy, scientific interest and quality of Bioibericas Blog devoted to osteoarthritis.The chondroprotection blog has had more than 5,500 visits from 3,000 unique users within less than six months.
It is a phase IV clinical trial currently being carried out in 38 medical centers in Spain, Germany, France and Poland. The objective of the MOVES (Multicenter Osteoarthritis InterVEntion trial with Sysadoas) it is to prove that combining chondroitin sulfate and glucosamine sulfate is as efficient as celecoxib for the treatment of moderate to severe pain in knee osteoarthritis.
The aim of these awards is to recognize innovative projects that contribute to improve disease management and attention to osteoarthritis patients.Candidates should submit their projects before September 30, 2012. The two awards, which include a 20,000 Euro prize each, will be given next November 8th, in an award ceremony hosted during the Annual Congress of the SECA.
The Jordi Gol Institute for Research in Primary Care (IDIAP) and Bioiberica Farma have signed a five-year research partnership agreement. Its objective is to boost biomedical research in the field of primary care, and, to be more precise, in the field of osteoarthritis. This partnership project aims to achieve new research milestones in the field of joint care.
The uncontrolled formation of new blood vessels in the synovial membrane (angiogenesis) may increase joint inflammation. Inflammation is associated to loss of cartilage tissue and pain, which causes rapid progression of the disease.